Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.
The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.
Our top-notch dedicated system is used to design specialised libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
The method includes detailed molecular simulations of the catalytic and allosteric binding pockets, along with ensemble virtual screening that considers their conformational flexibility. In the design of modulators, structural changes induced by reaction intermediates are taken into account to enhance activity and selectivity.
Our library is unique due to several crucial aspects:
partner
Reaxense
upacc
Q9BYT8
UPID:
NEUL_HUMAN
Alternative names:
Angiotensin-binding protein; Microsomal endopeptidase; Mitochondrial oligopeptidase M; Neurotensin endopeptidase
Alternative UPACC:
Q9BYT8; Q9ULJ4
Background:
Neurolysin, mitochondrial, known for its alternative names such as Angiotensin-binding protein, Microsomal endopeptidase, and Neurotensin endopeptidase, plays a crucial role in hydrolyzing oligopeptides including neurotensin, bradykinin, and dynorphin A. It acts as a regulator of the cannabinoid signaling pathway by mediating the degradation of hemopressin.
Therapeutic significance:
Understanding the role of Neurolysin, mitochondrial could open doors to potential therapeutic strategies.